Fernando Bianco
Overview
Explore the profile of Fernando Bianco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Gomez E, Martinez-Salamanca J, Bianco F, Miles B, Burgos J, Justo Quintas J, et al.
World J Urol
. 2024 Jul;
42(1):395.
PMID: 38985190
Purpose: To assess the clinical performance of ProsTAV, a blood-based test based on telomere associate variables (TAV) measurement, to support biopsy decision-making when diagnosing suspicious prostate cancer (PCa). Methods: Preliminary...
2.
Cocci A, Pezzoli M, Bianco F, Blefari F, Bove P, Cornud F, et al.
Asian J Urol
. 2024 Apr;
11(2):271-279.
PMID: 38680587
Objective: To evaluate transperineal laser ablation (TPLA) with Echolaser® (Echolaser® TPLA, Elesta S.p.A., Calenzano, Italy) as a treatment for benign prostatic hyperplasia (BPH) and prostate cancer (PCa) using the Delphi...
3.
Rodriguez-Sanchez L, Emberton M, de Reijke T, Stricker P, Minana B, Bianco F, et al.
World J Mens Health
. 2023 Oct;
42(2):245-255.
PMID: 37853538
No abstract available.
4.
Gomez Gomez E, Cano Castineira R, Burgos J, Rodriguez Antolin A, Miles B, Martinez Salamanca J, et al.
Prostate
. 2023 Jul;
83(14):1323-1331.
PMID: 37409738
Background: Current pathways in early diagnosis of prostate cancer (PCa) can lead to unnecessary biopsy procedures. Here, we used telomere analysis to develop and evaluate ProsTAV®, a risk model for...
5.
Luna E, Rodriguez D, Barrios D, Hernandez H, Bianco F, Gheiler E
J Sex Med
. 2022 Aug;
19(9):1472-1478.
PMID: 35933304
Background: Most of the published literature addressing the satisfaction postinflatable penile implant (IPP) placement includes non-validated surveys. Aim: The study aims to report the survey outcomes of the English version...
6.
Patel N, Sedrakyan A, Bianco F, Etzioni R, Gorin M, Hsu W, et al.
Urol Oncol
. 2022 Jun;
40(7):354.
PMID: 35654645
No abstract available.
7.
Manfredi C, Fernandez-Pascual E, Arcaniolo D, Emberton M, Sanchez-Salas R, Artigas Guix C, et al.
Eur Urol Focus
. 2021 Sep;
8(4):942-957.
PMID: 34538633
Context: Prostate-specific membrane antigen (PSMA) positron emission tomography/magnetic resonance imaging (PET/MRI) is a novel imaging technique with several potential applications in the prostate cancer (PCa) setting. Objective: To perform a...
8.
Marra G, P Laguna M, Walz J, Pavlovich C, Bianco F, Gregg J, et al.
Minerva Urol Nephrol
. 2021 Jan;
74(5):581-589.
PMID: 33439577
Background: Focal therapy (FT) for prostate cancer (PCa) is promising. However, long-term oncological results are awaited and there is no consensus on follow-up strategies. Molecular biomarkers (MB) may be useful...
9.
Patel N, Sedrakyan A, Bianco F, Etzioni R, Gorin M, Hsu W, et al.
Urol Oncol
. 2019 Sep;
37(12):988-990.
PMID: 31522862
Introduction: We examined the most recent Surveillance, Epidemiology, and End Results release to corroborate temporal trends in nonmetastatic and distant prostate cancer metastases in the United States. Methods: Surveillance, Epidemiology,...
10.
Linares-Espinos E, Carneiro A, Martinez-Salamanca J, Bianco F, Castro-Alfaro A, Cathelineau X, et al.
Minerva Urol Nefrol
. 2018 Apr;
70(3):252-263.
PMID: 29664243
Introduction: The aim of this study was to review the oncological and functional outcomes of new and established primary focal treatments (FT) for localized prostate cancer (PCa). Evidence Acquisition: We...